Afatinib (a second generation of EGFR-inhibitor) combined with TMZ synergistically inhibited cell proliferation, clonogenicity, invasion and motility of cultured glioma cells expressing EGFRvIII and prevented progression of intracranially implanted U87-MG EGFRvIII cells [38]. The gene discussed is EGFR; the disease is central nervous system cancer.